As opposed to what was observed when CD34 immunostaining was employed, in tumors with high-intensity tumor budding, we did not observe differences in MVD, assessed by CD105 immunostaining, between the budding area and the area outside the budding. This evidence concerns the gene CD34 and neoplasm.